|
|
|
|
|
★ ★ ★ BULLISH On The Breakout / Next Flight (OTCQB) ARTH ★ ★ ★
|
|
|
|
|
|
|
(OTCQB) ARTH - Flag, Pennant (Continuation) BULLISH On The BREAKOUT?
Flags and Pennants are short-term continuation patterns that mark a small consolidation before the previous move resumes. These patterns are usually preceded by a sharp advance or decline with heavy volume, and mark a mid-point of the move.
1. Sharp Move: To be considered a continuation pattern, there should be evidence of a prior trend. Flags and pennants require evidence of a sharp advance or decline on heavy volume. These moves usually occur on heavy volume and can contain gaps. This move usually represents the first leg of a significant advance or decline & the flag/pennant is merely a pause.
2. Flagpole: The flagpole is the distance from the first resistance or support break to the high or low of the flag/pennant. The sharp advance (or decline) that forms the flagpole should break a trend line or resistance/support level. A line extending up from this break to the high of the flag/pennant forms the flagpole.
3. Flag: A flag is a small rectangle pattern that slopes against the previous trend. If the previous move was up, then the flag would slope down. If the move was down, then the flag would slope up. Because flags are usually too short in duration to actually have reaction highs and lows, the price action just needs to be contained within two parallel trend lines.
4. Pennant: A pennant is a small symmetrical triangle that begins wide and converges as the pattern matures (like a cone). The slope is usually neutral. Sometimes there will not be specific reaction highs and lows from which to draw the trend lines and the price action should just be contained within the converging trend lines.
5. Duration: Flags and pennants are short-term patterns that can last from 1 to 12 weeks. There is some debate on the timeframe and some consider 8 weeks to be pushing the limits for a reliable pattern. Ideally, these patterns will form between 1 and 4 weeks. Once a flag becomes more than 12 weeks old, it would be classified as a rectangle. A pennant more than 12 weeks old would turn into a symmetrical triangle. The reliability of patterns that fall between 8 and 12 weeks is debatable.
6. Break: For a bullish flag or pennant, a break above resistance signals that the previous advance has resumed. For a bearish flag or pennant, a break below support signals that the previous decline has resumed.
7. Volume: Volume should be heavy during the advance or decline that forms the flagpole. Heavy volume provides legitimacy for the sudden and sharp move that creates the flagpole. An expansion of volume on the resistance (support) break lends credence to the validity of the formation and the likelihood of continuation.
8. Targets: The length of the flagpole can be applied to the resistance break or support break of the flag/pennant to estimate the advance or decline. Learn more: http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:flag_pennant_continuation
|
|
|
|
|
Welcome To Arch Therapeutics, Inc. (OTCQB: ARTH)
|
|
|
|
Arch Therapeutics, Inc. (Arch) is a biotechnology company developing an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis*) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, “stasis and barrier applications.”
Physicians, industry and patients could benefit greatly from a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in a variety of consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools designed to resolve these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.
Arch’s products are currently progressing in preclinical development. The first product, AC5 Surgical Hemostatic Device,™ is designed to achieve hemostasis in minimally invasive (laparoscopic**) and open surgical procedures and is intended to be regulated as a medical device.
Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything currently on the market.
AC5™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision directly into the wound area.
Because it is not sticky or glue-like, it is ideal for use in the laparoscopic setting – a challenge for much of the competition. Furthermore, it is transparent, enabling a surgeon to operate through it in order to prophylactically stop bleeding as it starts – an important advancement we have branded as Crystal Clear Surgery™.
Most importantly, time to hemostasis (TTH) for AC5™ is typically measured in seconds, rather than the many minutes as provided by much of the competition.
In preclinical tests, the AC5 Surgical Hemostatic Device™ has been simple, effective, and versatile. To date, biocompatibility has been excellent and healing of tissue treated with the device has been normal. This extraordinary concept, if successfully proven clinically, could eventually lead to product adoption available in every surgical setting across the globe.
*Hemostasis or haemostasis (from the Ancient Greek: αἱμόστασις haimóstasis "styptic (drug)") is the process of stopping bleeding, or preventing blood from leaking from damaged blood vessels and tissues. (The opposite of hemostasis is hemorrhage.)
**Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a modern surgical technique in which operations are performed through small incisions (usually 0.5–1.5 cm) as opposed to the larger incisions needed in open surgery. Keyhole surgery makes use of images displayed on TV monitors to magnify the surgical elements.
|
|
|
|
|
(OTCQB: ARTH) Recent Developments
|
|
|
|
|
Arch Therapeutics Receives Notice of Allowance for Patent Covering
Systemic Applications for Self-Assembling Peptides
U.S. Patent Addresses Use of the Self-Assembling Peptide Barrier Technology to Treat Disorders Involving Leaky Tight Junctions and Extracellular Matrix
FRAMINGHAM, MA--(Marketwired - Apr 25, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, received a notice of allowance from the U.S. Patent Office for a broad method-of-use patent that covers systemically administering the Company's self-assembling technology for treating damaged extracellular matrix and leaky tight junctions.
Many disorders are associated with leakage around blood vessels and within the tight junctions between cells. Such leakage can lead to fluid invading the tissues, causing a loss in blood pressure, organ dysfunction or failure, and death. Some examples include inflammatory bowel disease, sepsis and ischemic stroke.
Dr. Terrence W. Norchi, President and CEO of Arch Therapeutics, said, "This important patent lends additional support to Arch's planned products. It is another example of Arch's inventiveness in exploring better ways to address a range of areas of unmet or poorly met medical needs with our self-assembling peptide technology."
Arch has filed its own patent applications and, in addition, has licensed worldwide exclusive rights to certain patents and patent applications assigned jointly to MIT and Versitech Limited, the technology transfer company of the University of Hong Kong, and worldwide non-exclusive rights to another portfolio of patents assigned jointly to MIT and Versitech Limited. The applications and rights cover self-assembling compositions and methods of making and using such compositions for medical applications, including stopping bleeding; preventing the movement of bodily fluids, contaminants, etc., within or on the human body; preventing adhesions; treatment of leaky or damaged tight junctions; and reinforcement of weak or damaged vessels, such as aneurysms, with patents covering this technology in the United States, Europe, Japan, Canada, Israel, Australia, Hong Kong and China. Additional patent applications are pending in multiple jurisdictions.
|
|
|
|
|
(OTCQB: ARTH) Recent Headlines
|
|
|
|
- ARCH THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (Thu, Apr 28)
- Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016Marketwired (Tue, Apr 26)
- ARCH THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Mon, Apr 25)
- Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling PeptidesMarketwired (Mon, Apr 25)
- ARCH THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Mon, Apr 11)
- Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling PeptidesMarketwired (Mon, Apr 11)
- Pre-Market Alert - 4 Stocks That You Should Be Watching Today (Thu, Apr 7)
- ARCH THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 5)
- Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling PeptidesMarketwired(Tue, Apr 5)
- ARCH THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Mar 22)
- Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in HumansMarketwired(Tue, Mar 22)
- Arch Therapeutics, Inc. (OTCQB: ARTH) Patient Enrollment and Treatment in First Clinical Trial in Western EuropeAccesswire(Mon, Mar 14)
- ARCH THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, Mar 14)
- Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE MarkMarketwired(Mon, Mar 14)
- Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016Marketwired(Thu, Mar 10)
|
|
|
|
|
★ ★ ★ BULLISH On The Breakout / Next Flight (OTCQB) ARTH ★ ★ ★
|
|
|
|
|
|
|
|
|
|
|
|
| Disclaimer - Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing. You should not invest or trade in any penny stock unless are you are fully prepared, willing, able and expect to lose a hundred pct of your funds,including any profiled company or other company in any other manner mentioned or alluded to by carriage consulting as defined in any medium whatsoever. Carriage Consulting Group Compensation: three thousand dollars for a one day awareness campaign on ARTH from a 3rdparty The service is provided as a guide to some available investments only, which must be tempered by the investment experience and independent decision making process of the subscriber. The accuracy of issuer documents and information that is submitted to and, its affiliated members and its management for inclusion on this site is principally the responsibility of the particular issuer and its management, its affiliated members and its management is neither responsible for, nor undertakes any steps to check, the accuracy of any information provided by featured companies to potential investors. You should confirm to your own satisfaction the veracity of any info prior to entering into any investment. |
|
|
